ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy
donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.
The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to
evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of
ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.